A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors - Concepedia

Concepedia

Publication | Closed Access

A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

194

Citations

29

References

2010

Year

Razelle Kurzrock, Amita Patnaik, Joseph Aisner, Terri Warren, Stephen Leong, Robert S. Benjamin, Sabine Eckhardt, Joseph Eid, Gérard Greig, Kai Habben,

Clinical Cancer Research

Abstract

R1507 is well tolerated and shows antitumor activity in patients with solid neoplasms, in particular Ewing's sarcoma. The recommended dose for the weekly schedule is 9 mg/kg qW.

References

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study June M. Chan, Meir J. Stampfer, Edward L. Giovannucci, Science	1998	2K
Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3 Jianchao Ma, Michaël Pollak, E. Giovannucci, JNCI Journal of the National Cancer Institute	1999	1.1K
Insulin-Like Growth Factor-I (IGF-I) and IGF Binding Protein-3 as Predictors of Advanced-Stage Prostate Cancer June M. Chan JNCI Journal of the National Cancer Institute	2002	436
EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3 Alexandre Prieur, Franck Tirode, Pinchas Cohen, Molecular and Cellular Biology Signaling PathwayGene ProfilingRna InterferenceMedicineCrucial Role	2004	415
A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Edward L. Giovannucci, Michaël Pollak, Elizabeth A. Platz, PubMed Epidemiology Of CancerGynecologyPathologyTumor BiologyIgf-1 Level	2000	404
Plasma Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-Binding Proteins, and Prostate Cancer Risk: a Prospective Study Pär Stattin JNCI Journal of the National Cancer Institute	2000	403
Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1 Anthony W. Tolcher, John Sarantopoulos, Amita Patnaik, Journal of Clinical Oncology	2009	307
Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden Richard Palmqvist Gut	2002	276
Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Katia Scotlandi, Stefania Benini, Manuela Sarti, PubMed Tumor InnervationImmunologyPathologyTumor BiologyNeuro-oncology	1996	232

Page 1